Abstract
Acute myeloid leukaemia with mutated IDH1 is most frequently found in the European LeukemiaNet intermediate risk group. The incidence of IDH1 mutations increases with age, and older patients (aged >75 years) with IDH1-mutated acute myeloid leukaemia who are ineligible for intensive chemotherapy are highly sensitive to azacitidine combined with venetoclax.1 A randomised phase 3 trial2 showed that the IDH1 inhibitor ivosidenib combined with azacitidine significantly prolonged event-free survival and overall survival of older patients with IDH1 mutated acute myeloid leukaemia compared with placebo and azacitidine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
